Pemafibrate .

Hypertriglyceridemia together with reduced HDL-C is a risk factor for Atherosclerotic Cardiovascular Disease (ASCVD). A sedentary lifestyle, a lipid-rich diet and similar factors make high triglyceride (TG) harder to control. Fibrates are considered the preferred treatment for reducing TG. They work mainly by binding to and activating peroxisome proliferator activated receptor alpha (PPARα), a nuclear receptor. But conventional fibrates have low selectivity and potency for binding to PPARα. As a result, they sometimes fail to bring TG down to the desired level, and they are often linked with various side effects. Pemafibrate is a new selective PPARα modulator, and it is strongly effective in treating hypertriglyceridemia and low HDL-C levels. Its unique Y-shaped structure lets it bind tightly to the PPARα receptor. The structure of Pemafibrate contains benzoxazole and phenoxyalkyl side-chains along with the common fibric acid group, which gives high selectivity for PPARα, strong interaction with the receptor, and maximum activation of the receptor. Thus, Pemafibrate shows over 2,500-fold greater potency for PPARα compared to conventional fibrates and gives a better therapeutic outcome.